retatrutide type 2 diabetes trial nct Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Efficacy and safety of retatrutide,

These discussions highlight real barriers to medication access that dont exist in US-focused forums, making Canadian perspectives particularly valuable for understanding practical treatment challenges

Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)

As we age, natural GH production declines, and the pituitary gland becomes less responsive to GHSs

Incorporate a liposomal glutathione supplement into your morning routine

But momentum is spreading: While only 27 percent provide coverage for weight loss, 13 percent are considering doing so

If youre ready to explore how dermal fillers can benefit you throughout your weight loss journey, our MFI team would love to guide you through your options